The Short-term Pulsatile Ventricular Assist Device for Postcardiotomy Cardiogenic Shock: A Clinical Trial in China
| Autor: | Huanlei Huang, Ruixin Fan, Yue-heng Wu, Ding-hua Yi, Ruo-bin Wu, Shang-yi Ji, Shao-yi Zheng, Anheng Cheng, Zhengxiang Luo, Xiaohua Zhang, Xuejun Xiao, Chun-xiu Ye |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male China medicine.medical_specialty Time Factors medicine.drug_class medicine.medical_treatment Shock Cardiogenic Biomedical Engineering Medicine (miscellaneous) Bioengineering Biomaterials Sepsis Postoperative Complications Internal medicine medicine Humans Cardiac Surgical Procedures Survival rate Aged business.industry Cardiogenic shock Anticoagulant Anticoagulants Equipment Design General Medicine Middle Aged medicine.disease Cardiac surgery Clinical trial Treatment Outcome Pulsatile Flow Ventricular assist device Cohort Cardiology Female Heart-Assist Devices business |
| Zdroj: | Artificial Organs. 33:373-377 |
| ISSN: | 1525-1594 0160-564X |
| DOI: | 10.1111/j.1525-1594.2009.00729.x |
| Popis: | Despite the recent advances in myocardial protection, surgical techniques, intra-aortic balloon therapy, and maximal pharmacological support, postoperative ventricular dysfunction continues to occur in 0.5–1.0% of all patients undergoing cardiac surgery. Ventricular assist device (VAD) is an important therapeutic adjunct in treating patients with profound ventricular dysfunction with postcardiotomy cardiogenic shock. The purpose of this report was to describe the clinical results with the China-made Luo-Ye VAD as a short-term circulatory support. From May 1998 to December 2006, 17 patients with postcardiotomy cardiogenic shock were supported by the Luo-Ye VAD. Of these patients, 10 were males and seven were females with a mean age of 49.6 years (range 36–68 years). All cases were supported by left VAD (LVAD). Mean duration of support was 46.3 h (range 13–113 h). A criteria of insertion was established to standardize implantation criteria. Among the 17 patients treated with LVAD, eight (47.1%) patients were weaned from support and seven (41.2%) patients were discharged from hospital. Ten (58.8%) patients died while on LVAD support (nine cases) or shortly after weaning (one case). The causes of death in the entire group were cardiac (40%), renal failure (20%), neurologic (10%), sepsis (10%), and multiple organ system failure (20%). The complications were represented by bleeding, renal failure, neurologic event, infection, ventricular arrhythmias, etc. The Luo-Ye VAD functioned well and proved to be useful in patients with postcardiotomy cardiogenic shock. It carries a less-postoperative anticoagulant and a low incidence of VAD-related complications. The survival rate was encouraging in our small cohort of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|